
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded capsule containing metoprolol tartrate, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing metoprolol are listed in capsule, tablet, injection and solution forms.
This is a solid, nonaqueous dose form. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Metoprolol is a beta-1 selective beta-blocker that compounding pharmacies prepare by prescription as oral liquids and other oral forms.
Metoprolol is a cardioselective beta-1 adrenergic blocker. It slows the heart rate and reduces the force of each heartbeat and blood pressure, which lowers the heart's demand for oxygen. Lopressor (metoprolol tartrate, Validus) oral solution is FDA-approved for high blood pressure, for long-term treatment of angina, and for hemodynamically stable patients with a heart attack, to reduce the risk of cardiovascular death; metoprolol tartrate is also manufactured as tablets. Toprol-XL (metoprolol succinate extended-release tablets) is approved for high blood pressure, angina and heart failure. A prescriber may order metoprolol compounded when a patient needs a strength, flavor or dye-free liquid that is not manufactured, or a different oral form. Compounded preparations are not FDA-approved and require a prescription.
Current Lopressor and Toprol-XL labels carry no boxed warning, but they warn that stopping metoprolol suddenly can worsen chest pain or trigger a heart attack, so do not stop it without your prescriber's plan to taper. Do not use it if you have a very slow heart rate, second or third degree heart block, sick sinus syndrome without a pacemaker, cardiogenic shock or decompensated heart failure. It can hide signs of low blood sugar and an overactive thyroid, worsen breathing in bronchospastic disease, and make allergic reactions less responsive to usual doses of epinephrine. CYP2D6 inhibitors, reserpine, MAO inhibitors, digoxin, clonidine, diltiazem and verapamil can interact. The label reports observational pregnancy data without a link to birth defects; LactMed says milk levels are low and advises watching the infant for slow heart rate and listlessness. For dizziness, shortness of breath or swelling, talk to your prescriber or pharmacist.
Metoprolol is a beta-1 selective adrenergic blocker without intrinsic sympathomimetic or membrane-stabilizing activity (StatPearls). Per the Lopressor label, oral bioavailability of immediate-release metoprolol is about 50% because of saturable first-pass metabolism, about 10% is bound to albumin, volume of distribution is 3.2 to 5.6 L/kg, and the drug crosses the blood-brain barrier and the placenta. Metabolism is mainly by CYP2D6; mean elimination half-life is 3 to 4 hours, rising to 7 to 9 hours in poor CYP2D6 metabolizers, and about 95% of a dose is recovered in urine. Labeled indications: Lopressor for hypertension, angina pectoris and hemodynamically stable myocardial infarction; Toprol-XL for hypertension, angina pectoris and heart failure. StatPearls lists off-label use for supraventricular and ventricular tachyarrhythmias, migraine prevention, essential tremor and adjunctive treatment of thyrotoxicosis. Dosing is per prescriber; when discontinuing, the label advises a gradual reduction over 1 to 2 weeks with monitoring. Monitor blood pressure, heart rate, ECG during parenteral use, and blood glucose in patients with diabetes (StatPearls). Metoprolol is not a controlled substance.
Swallow each capsule whole with a glass of water, unless your label says otherwise. Do not crush, chew or open the capsule unless your pharmacist tells you it is safe to do so. Take it at the times shown on your prescription label. If you miss a dose or are unsure how to take it, call the pharmacy.
Capsules are nonaqueous, so under USP <795> they usually carry a beyond-use date of up to 180 days when no other stability data apply. Keep the vial tightly closed at room temperature, away from heat, moisture and direct light, and out of reach of children. Discard any capsules left after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth